Overview
Welcome to the 2026 Annual Conference of the Chinese Antibody Society (ChAbS)! We are thrilled to host this year's event at the Boston Marriott Cambridge in Cambridge, MA, on Saturday, May 9, and Sunday, May 10, 2026.
In celebration of our 10th anniversary, this year's theme is "Ten Years Together: Forging the Future of Antibody Therapeutics." This special two-day event will showcase a decade of innovation and highlight recent advances in antibody engineering, translational research, and biologics development. Join us for insightful symposia, expert-led presentations, and valuable networking opportunities with academic and industry leaders as we work together to shape the next decade of the field.
Speakers
Jingsong Wang
Founder, Chairman, CEO at Harbour BioMed; Chairman at Nona Biosciences
Hiroki Akiba
Lecturer, Kyoto University
Kaisong Zhou
Chairman & CEO, Altruist Biologics
Kyoji Tsuchikama
Associate Professor, University of Texas Health Science Center
Marie Zhu
CTO, WuXi XDC
Nils Lonberg
Executive in Residence, Canaan Partners & CEO, Tripeaks Therapeutics
Per Jr. Greisen
Chief Computation Biologist, BioMap
Tianlei Ying
Distinguished Professor, Fudan University
Weian Zhao
Founder and CEO, Aureka Biotechnologies
Zhaohui Sunny Zhou
Professor, Northeastern University
Jimmy Li
CEO, WuXi XDC
Christoph Rader
CTO, Aethon Therapeutics
Jing Li
Founder and CEO, VelaVigo
Kevin Yang
Principal Researcher, Microsoft
Likun Gong
Professor and Director, Chinese Academy of Sciences
Michell Ho
Senior Invesstigator and Deputy Chief, NCI / NIH
Oxana Beskrovnaya
Chief Innovation Officer, Dyne Therapeutics
Surge Biswas
Founder & CEO, Nabla Bio
Timothy Springer
Latham Family Professor, Harvard Medical School/Boston Children's Hospital
Yu Qiu
Executive Director, AstraZeneca
Zhiqiang An
Professor, Vice President of Drug Discovery, UTH
Agenda
Poster Presentations
This year, we have again received numerous submissions covering innovative technologies in antibody drug discovery and development, as well as significant research and clinical advancements. Following careful review by the committee and communication with the awardees, three abstracts have been selected for oral presentations at 1:35pm on May 10.
-
Non-blocking anti-PD-L1 nanobody conjugated to TLR7 agonist mediates macrophage/NK cell-associated antitumor effects. The first author is Yiru Long from Shanghai Institute of Materia Medica.
-
Trispecific Antibody Targeting PD-1 and IL-18R Enhances Antitumor Immunity with Superior Safety Profile. The first author is Yichen Wang from Fudan University.
-
Discovery and preclinical development of a PD-1/IL-2v bispecific antibody cytokine fusion protein with AI-powered MoleculeOS (MOS) technology. The first author is Hongchuan Liu from MoleculeMind.
Additionally, a total of 20 abstracts (including the above three) were selected for poster presentations, and attendees are welcome to engage in discussions at the annual conference.
Thank you to our sponsors!
Sponsorship inquiries
If you are interested in sponsoring this annual conference or future events, please contact: management@chabs.org